Applied BioCode Corporation (TPE:6598)

Market Cap	2.47B +13.5%
Revenue (ttm)	443.69M +14.9%
Net Income	-207.78M
EPS	-2.02
Shares Out	102.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	345,235
Average Volume	349,120
Open	24.15
Previous Close	24.05
Day's Range	23.35 - 24.65
52-Week Range	17.00 - 25.65
Beta	0.80
RSI	51.88
Earnings Date	Mar 16, 2026

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Country: Cayman Islands
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6598

Financial Performance

In 2024, Applied BioCode's revenue was 343.07 million, a decrease of -13.18% compared to the previous year's 395.17 million. Losses were -260.81 million, 58.8% more than in 2023.